HLF241101C7000
- 0.45
- -0.10-18.18%
Herbalife Newsroom
Herbalife Analyst Ratings
Citi Maintains Herbalife(HLF.US) With Buy Rating, Cuts Target Price to $13
Herbalife's Digital Engagement and Market Trends Support Buy Rating Despite Lowered Target Price
Citi Maintains Herbalife(HLF.US) With Buy Rating, Maintains Target Price $16
Buy Rating Affirmed: Signs of Recovery in Web and App Traffic Indicate Strengthening Market Position for Herbalife
Citi Maintains Herbalife(HLF.US) With Buy Rating, Maintains Target Price $16
Buy Rating Affirmed: Herbalife's Positive Web Traffic and Share Price Return Outlook
BofA Securities Maintains Herbalife(HLF.US) With Sell Rating, Maintains Target Price $8
Herbalife Faces Sales Decline and Persisting Challenges: An Underperform Rating With a Price Objective of $8
Herbalife Analyst Ratings
B.Riley Financial Maintains Herbalife(HLF.US) With Buy Rating, Raises Target Price to $17
D.A. Davidson Maintains Herbalife(HLF.US) With Hold Rating, Announces Target Price $13
Hold Rating on Herbalife: Balancing Cost-Saving Success Against Revenue Shortfalls and Market Challenges
D.A. Davidson Sticks to Their Hold Rating for Herbalife (HLF)
Buy Rating Affirmed on Herbalife: Mixed Web Traffic and Strong App Engagement Signal Growth Potential
Herbalife Analyst Ratings
Herbalife's Buy Rating Backed by Positive Web and App Traffic Trends
Analysts Offer Insights on Healthcare Companies: Herbalife (HLF), Alignment Healthcare (ALHC) and Vaxcyte (PCVX)
D.A. Davidson Reaffirms Their Hold Rating on Herbalife (HLF)
Herbalife Analyst Ratings